Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials

AIMS/INTRODUCTION: Non‐alcoholic fatty liver disease (NAFLD) is increasingly common in patients with type 2 diabetes mellitus. Currently, some studies have found that sodium–glucose cotransporter 2 (SGLT2) inhibitors, a new hypoglycemic drug, can improve non‐alcoholic fatty liver in addition to its...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Baodi, Zhao, Yuhang, Dong, Bingzi, Zhou, Yue, Lv, Wenshan, Zhao, Wenjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477503/
https://www.ncbi.nlm.nih.gov/pubmed/32083798
http://dx.doi.org/10.1111/jdi.13237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477503/
https://www.ncbi.nlm.nih.gov/pubmed/32083798
http://dx.doi.org/10.1111/jdi.13237

Ejemplares similares